Rare Disease Focus Novartis is advancing RemIND data for Rhapsido in chronic inducible urticaria and del-brax for facioscapulohumeral muscular dystrophy, with ongoing sNDA filings and global submissions, signaling strong demand for specialized development partnerships, regulatory strategy, and patient-centric access programs to support high-need indications.

Data & Analytics The company leverages Power BI and SAP Gateway among other tools, creating opportunities to offer integrated data platforms, advanced trial analytics, real-world evidence generation, and streamlined regulatory reporting to accelerate submissions.

Trial Operations With Phase III and early-to-mid-stage studies underway, there is potential to partner on trial planning, patient recruitment optimization, CRO collaboration, and clinical logistics to scale complex trials efficiently.

Global Market Access Global multi-region approvals and active regulatory filings suggest openings for regulatory affairs outsourcing, health economics and outcomes research, payer strategy, and market access partnerships to support global launches.

Pipeline Growth Ongoing M&A activity and pipeline expansion indicate openness to co-development, licensing, and strategic investments to accelerate time-to-market and broaden therapy areas across immune-mediated and neuromuscular diseases.